Pharnext presenteert PLEOTHERAPY™ R&D Platform tijdens de 8e jaarlijkse Global Orphan Drug Conference
PARIS–(BUSINESS WIRE)– Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), een biofarmaceutisch bedrijf dat pioneert met een nieuwe aanpak voor de ontwikkeling van innovatieve geneesmiddelencombinaties op basis van big data genomics en kunstmatige intelligentie, maakt bekend dat Rodolphe Hajj, Ph.D., de Chief Pharmacology Officer van het bedrijf, een presentatie gaat geven tijdens het 8e jaarlijkse Global Orphan Drug Conference.
De presentatie zal als volgt plaatsvinden:
- Datum & tijdstip: woensdag 25 april om 4:40 pm EST
- Titel: “Next generation drug repurposing using network pharmacology to develop new therapeutic entities for rare diseases”
- Plaats: Gaylord National Harbor Hotel, Oxon Hill, MD, U.S.
Het team van Pharnext is ook voor het eerst als exposant aanwezig bij de American Academy of Neurology Annual 2018 Meeting (stand 908). Het evenement vindt plaats tussen 21-27 april 2018 in Los Angeles, CA, VS.
Mocht je interesse hebben om het managementteam van Pharnext te ontmoeten tijdens deze evenementen, dan kunt u een e-mail sturen aan contact@pharnext.com.
Pharnext to Showcase PLEOTHERAPY™ R&D Platform at the 8th Annual Global Orphan Drug Conference
PARIS–(BUSINESS WIRE)– Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced that Rodolphe Hajj, Ph.D., the Company’s Chief Pharmacology Officer, will present at the 8th Annual Global Orphan Drug Conference.
The presentation will take place as follows:
- Date & Time: Wednesday April 25th at 4:40 pm EST
- Title: “Next generation drug repurposing using network pharmacology to develop new therapeutic entities for rare diseases”
- Venue: Gaylord National Harbor Hotel, Oxon Hill, MD, U.S.
Pharnext’s team will also attend the 2018 American Academy of Neurology Annual Meeting as a first-time exhibitor (booth 908). The meeting will take place on April 21-27, 2018 in Los Angeles, CA, U.S.
If you are interested in meeting the Pharnext management team during these events, please send an email to contact@pharnext.com.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease 1A type and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big data genomics and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180419005935/en/
Contacts
Pharnext
Xavier Paoli
Chief Commercial Officer
+33 (0)1 41 09 22 3030
contact@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke
+49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki
+1 212 362 1200
matthew@sternir.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz
+33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Aurore Gangloff
Caroline Carmagnol
+33 (0)1 44 54 36 66
pharnext@alizerp.com
or
Media Relations (U.S.)
RooneyPartners
Kate Barrette
+1 212 223 0561
kbarrette@rooneyco.com
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr